Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011

Journal of Viral Hepatitis

Volumn 21, Issue 3, 2014, Pages 198-207

  Iversen, Jenny ^a   Grebely, J ^a   Topp, L ^b   Wand, H ^a   Dore, G ^a   Maher, L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b CANCER RESEARCH DIVISION   (Australia)

Author keywords

age; antiviral treatment; gender; hepatitis C virus; injection drug use; surveillance

Indexed keywords

ANTIVIRUS AGENT; DIAMORPHINE; HEPATITIS C ANTIBODY; INTERFERON; METHAMPHETAMINE; PEGINTERFERON ALPHA; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; AUSTRALIA; DRIED BLOOD SPOT TESTING; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HOMOSEXUALITY; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS LOAD;

AGE; ANTIVIRAL TREATMENT; GENDER; HEPATITIS C VIRUS; INJECTION DRUG USE; SURVEILLANCE;

ADULT; ANTIVIRAL AGENTS; AUSTRALIA; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; RISK FACTORS; SELF REPORT; SEROEPIDEMIOLOGIC STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84892791410     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12129     Document Type: Article

References (51)

1. Shepard CW, Finelli L, Alter MJ,. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5 (9): 558-567.
2. Grebely J, Dore GJ,. Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity. J Infect Dis 2011; 203 (5): 571-574.
3. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des JD, Talal AH,. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 2013; 56 (6): 806-816.
4. Hellard M, Sacks-Davis R, Gold J,. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49 (4): 561-573.
5. Dore GJ, Hellard M, Matthews GV, et al,. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010; 138 (1): 123-135.
6. Craxi A,. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55 (2): 245-264.
7. Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ,. An update on the management of hepatitis C: consensus guidelines from the Canadian association for the study of the liver. Can J Gastroenterol 2012; 26 (6): 359-375.
8. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49 (4): 1335-1374.
9. NCHECR. HIV/AIDS, Viral Hepatitis and Sexually Transmissible Infections in Australia Annual Surveillance Report 2009. Sydney, NSW: NCHCER, The University of New South Wales, 2009.
10. Grebely J, Raffa JD, Lai C, et al,. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16 (5): 352-358.
11. Mehta SH, Genberg BL, Astemborski J, et al,. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33 (3): 126-133.
12. Volk ML,. Antiviral therapy for hepatitis C: why are so few patients being treated? J Antimicrob Chemother 2010; 65 (7): 1327-1329.
13. Volk ML, Tocco R, Saini S, Lok AS,. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009; 50 (6): 1750-1755.
14. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK,. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56 (3): 385-389.
15. Lettmeier B, Muhlberger N, Schwarzer R, et al,. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008; 49 (4): 528-536.
16. Strathdee SA, Latka M, Campbell J, et al,. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis 2005; 40 (Suppl 5): S304-S312.
17. Dore GJ,. The changing therapeutic landscape for hepatitis C. Med J Aust 2012; 196 (10): 629-632.
18. Chung RT,. A watershed moment in the treatment of hepatitis C. N Engl J Med 2012; 366 (3): 273-275.
19. MacDonald M, Wodak AD, Ali R, et al,. HIV prevalence and risk behaviour in needle exchange attenders: a national study, The collaboration of Australian needle exchanges. Med J Aust 1997; 166 (5): 237-240.
20. Topp L, Iversen J, Wand H, Day C, Kaldor J, Maher L,. Representativeness of injecting drug users who participate in HIV surveillance: results from Australia's needle and syringe program survey. J Acquir Immune Defic Syndr 2008; 47 (5): 632-638.
21. MacDonald MA, Wodak AD, Dolan KA, van BI, Cunningham PH, Kaldor JM,. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. Collaboration of Australian NSPs. Med J Aust 2000; 172 (2): 57-61.
22. Grebely J, Bryant J, Hull P, et al,. Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. J Viral Hepat 2011; 18 (4): e104-e116.
23. Kramer JR, Kanwal F, Richardson P, Giordano TP, Petersen LA, El-Serag HB,. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol 2011; 106 (3): 483-491.
24. Gidding HF, Law MG, Amin J, et al,. Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Med J Aust 2011; 194 (8): 398-402.
25. Conway B, Grebely J, Tossonian H, Lefebvre D, de VS,. A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective. Clin Infect Dis 2005; 41 (Suppl 1): S73-S78.
26. Bini EJ, Brau N, Currie S, et al,. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005; 100 (8): 1772-1779.
27. Kanwal F, Hoang T, Spiegel BM, et al,. Predictors of treatment in patients with chronic hepatitis C infection-role of patient versus nonpatient factors. Hepatology 2007; 46 (6): 1741-1749.
28. NCHECR. Epidemiological and Economic Impact of Potential Increased Hepatitis C Treatment Uptake in Australia 2010. Sydney, NSW: National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, 2010.
29. Kirby Institute,. HIV, Viral Hepatitis and Sexually Transmissible Infections in Australia, Annual Surveillance Report 2012. Sydney, NSW: The Kirby Institute, The University of New South Wales, 2012.
30. Boonwaat L, Haber PS, Levy MH, Lloyd AR,. Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C. Med J Aust 2010; 192 (9): 496-500.
31. Lloyd AR, Clegg J, Lange J, et al,. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. Clin Infect Dis 2013; 56 (8): 1078-1084.
32. Islam MM, Topp L, Conigrave KM, et al,. Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre. J Subst Abuse Treat 2012; 43 (4): 440-445.
33. Treloar C, Newland J, Rance J, Hopwood M,. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. J Viral Hepat 2010; 17 (12): 839-844.
34. Grebely J, Oser M, Taylor LE, Dore GJ,. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis 2013; 207 (Suppl 1): S19-S25.
35. Thomas DL, Leoutsakas D, Zabransky T, Kumar MS,. Hepatitis C in HIV-infected individuals: cure and control, right now. J Int AIDS Soc 2011; 14: 22.
36. Morrill JA, Shrestha M, Grant RW,. Barriers to the treatment of hepatitis C, Patient, provider, and system factors. J Gen Intern Med 2005; 20 (8): 754-758.
37. Grebely J, Dore GJ,. An expanding role for primary care providers in the treatment of hepatitis C virus infection in the community. Hepatology 2011; 54 (6): 2258-2260.
38. Edlin BR, Kresina TF, Raymond DB, et al,. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005; 40 (Suppl 5): S276-S285.
39. Arora S, Thornton K, Murata G, et al,. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011; 364 (23): 2199-2207.
40. Hill WD, Butt G, Alvarez M, Krajden M,. Capacity enhancement of hepatitis C virus treatment through integrated, community-based care. Can J Gastroenterol 2008; 22 (1): 27-32.
41. Litwin AH, Harris KA Jr, Nahvi S, et al,. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat 2009; 37 (1): 32-40.
42. Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD,. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003; 138 (3): 187-190.
43. Farley JD, Wong VK, Chung HV, et al,. Treatment of chronic hepatitis C in Canadian prison inmates. Can J Gastroenterol 2005; 19 (3): 153-156.
44. Alter HJ, Liang TJ,. Hepatitis C: the end of the beginning and possibly the beginning of the end. Ann Intern Med 2012; 156 (4): 317-318.
45. Boutwell AE, Allen SA, Rich JD,. Opportunities to address the hepatitis C epidemic in the correctional setting. Clin Infect Dis 2005; 40 (Suppl 5): S367-S372.
46. Grebely J, Raffa JD, Lai C, Krajden M, Conway B, Tyndall MW,. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol 2007; 21 (7): 447-451.
47. Micallef JM, Kaldor JM, Dore GJ,. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006; 13 (1): 34-41.
48. Bryant J, Topp L, Hopwood M, Iversen J, Treloar C, Maher L,. Is point of access to needles and syringes related to needle sharing? Comparing data collected from pharmacies and needle and syringe programs in south-east Sydney. Drug Alcohol Rev 2010; 29 (4): 364-370.
49. Martin NK, Vickerman P, Miners A, et al,. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 2012; 55 (1): 49-57.
50. Hellard ME, Jenkinson R, Higgs P, et al,. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust 2012; 196 (10): 638-641.
51. Martin NK, Vickerman P, Hickman M,. Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol 2011; 274 (1): 58-66.